Urgent.News

What's breaking now, across thousands of outlets.

Business

Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry?

NTLA wins FDA priority review for lonvo-z, with a March 10, 2027 decision, potentially adding its first product, while nex-z studies are progressing well.

We haven't written up this one. Quartz has the full story — the link below goes straight to it.

Read the original at qz.com →

More in Business

More from Tuesday 22 September →